Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 8;100(40):e27368. doi: 10.1097/MD.0000000000027368

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0

PMC Copyright notice

Risk of herpes zoster with each biological drug compared with non-biological therapies. Compared with non-biological therapies, the risk of HZ associated with infliximab (OR: 2.43; 95% CI: 1.31–4.50; I² = 0%) and etanercept (OR: 1.65; 95% CI: 1.07–2.56; I² = 0%) increased significantly; however, adalimumab (OR: 1.21; 95% CI: 0.64–2.30; I² = 0%), ustekinumab (OR: 2.20; 95% CI: 0.89–5.44; I² = 0%), alefacept (OR: 1.46; 95% CI: 0.20–10.47; I² = 0%), and efalizumab (OR: 1.58; 95% CI: 0.22–11.34; I² = 0%) did not show increased risk. CI = confidence interval, OR = odds ratio.